CU20100113A7 - Péptido para la terapia del cáncer - Google Patents

Péptido para la terapia del cáncer

Info

Publication number
CU20100113A7
CU20100113A7 CU20100113A CU20100113A CU20100113A7 CU 20100113 A7 CU20100113 A7 CU 20100113A7 CU 20100113 A CU20100113 A CU 20100113A CU 20100113 A CU20100113 A CU 20100113A CU 20100113 A7 CU20100113 A7 CU 20100113A7
Authority
CU
Cuba
Prior art keywords
peptide
increase
cancer therapy
nuclear localization
cancer
Prior art date
Application number
CU20100113A
Other languages
English (en)
Other versions
CU23897B1 (es
Inventor
Argueelles Brizaida Maylin Oliva
Maso Julio Raul Fernandez
Vallespi Maribel Guerra
Lasa Alexis Musacchio
Valdes Jeovanis Gil
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU2010000113A priority Critical patent/CU23897B1/es
Priority to ARP110101831A priority patent/AR081259A1/es
Priority to MX2012013923A priority patent/MX2012013923A/es
Priority to AU2011260745A priority patent/AU2011260745B2/en
Priority to US13/700,286 priority patent/US8729226B2/en
Priority to EP11728172.5A priority patent/EP2578227B1/en
Priority to UAA201215130A priority patent/UA112522C2/uk
Priority to CN201180026853.7A priority patent/CN102917725B/zh
Priority to BR112012030668-5A priority patent/BR112012030668B1/pt
Priority to CA2799066A priority patent/CA2799066C/en
Priority to PCT/CU2011/000003 priority patent/WO2011150897A2/es
Priority to JP2013512751A priority patent/JP5827322B2/ja
Priority to KR1020127033777A priority patent/KR101847170B1/ko
Priority to DK11728172.5T priority patent/DK2578227T3/en
Priority to RU2012157289/10A priority patent/RU2577993C2/ru
Publication of CU20100113A7 publication Critical patent/CU20100113A7/es
Priority to ZA2012/08905A priority patent/ZA201208905B/en
Publication of CU23897B1 publication Critical patent/CU23897B1/es
Priority to US14/075,276 priority patent/US9145554B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención describe un método para el tratamiento del cáncer mediante el incremento de la localización nuclear de la proteína COMMD1, lo cual se asocia con la disminución o bloqueo de la proliferación de la célula de cáncer. La invención se relaciona, además, con el uso de agentes que incrementan la localización nuclear de la proteína COMMD1 en la fabricación de un medicamento para la terapia del cáncer. Dichos agentes pueen ser péptidos o proteínas, entre otros compuestos. La invención también se relaciona con la optimización de un péptido, proveniente de la secuencia HARIKPTFRRLKWKKYKGKFW, para incrementar la localización nuclear de la proteína COMMD1 y , de esa forma, aumentar el efecto antitumoral de dicho péptido.
CU2010000113A 2010-05-31 2010-05-31 Péptido para la terapia del cáncer CU23897B1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer
ARP110101831A AR081259A1 (es) 2010-05-31 2011-05-27 Metodo para la terapia del cancer
CA2799066A CA2799066C (en) 2010-05-31 2011-05-31 Method for cancer therapy
JP2013512751A JP5827322B2 (ja) 2010-05-31 2011-05-31 癌の治療方法
US13/700,286 US8729226B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
EP11728172.5A EP2578227B1 (en) 2010-05-31 2011-05-31 Cancer therapy method
UAA201215130A UA112522C2 (uk) 2010-05-31 2011-05-31 Спосіб терапії злоякісної пухлини
CN201180026853.7A CN102917725B (zh) 2010-05-31 2011-05-31 用于癌症治疗的肽
BR112012030668-5A BR112012030668B1 (pt) 2010-05-31 2011-05-31 Peptídeos, composição farmacêutica, e combinação farmacêutica
MX2012013923A MX2012013923A (es) 2010-05-31 2011-05-31 Metodo para la terapia del cancer.
PCT/CU2011/000003 WO2011150897A2 (es) 2010-05-31 2011-05-31 Método para la terapia del cáncer
AU2011260745A AU2011260745B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
KR1020127033777A KR101847170B1 (ko) 2010-05-31 2011-05-31 암 치료 방법
DK11728172.5T DK2578227T3 (en) 2010-05-31 2011-05-31 METHOD OF CANCER THERAPY
RU2012157289/10A RU2577993C2 (ru) 2010-05-31 2011-05-31 Способ терапии злокачественной опухоли
ZA2012/08905A ZA201208905B (en) 2010-05-31 2012-11-26 Cancer therapy method
US14/075,276 US9145554B2 (en) 2010-05-31 2013-11-08 Cancer therapy method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer

Publications (2)

Publication Number Publication Date
CU20100113A7 true CU20100113A7 (es) 2012-06-21
CU23897B1 CU23897B1 (es) 2013-05-31

Family

ID=45067129

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer

Country Status (16)

Country Link
US (2) US8729226B2 (es)
EP (1) EP2578227B1 (es)
JP (1) JP5827322B2 (es)
KR (1) KR101847170B1 (es)
CN (1) CN102917725B (es)
AR (1) AR081259A1 (es)
AU (1) AU2011260745B2 (es)
BR (1) BR112012030668B1 (es)
CA (1) CA2799066C (es)
CU (1) CU23897B1 (es)
DK (1) DK2578227T3 (es)
MX (1) MX2012013923A (es)
RU (1) RU2577993C2 (es)
UA (1) UA112522C2 (es)
WO (1) WO2011150897A2 (es)
ZA (1) ZA201208905B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2105567C1 (ru) * 1995-12-01 1998-02-27 Сергей Юрьевич Родионов Способ лечения злокачественных опухолей
CU23582A1 (es) 2006-02-24 2010-10-30 Ct Ingenieria Genetica Biotech Péptidos con capacidad anti-tumoral e inmunomoduladora
CU23674A1 (es) * 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Also Published As

Publication number Publication date
WO2011150897A3 (es) 2012-03-15
CA2799066A1 (en) 2011-12-08
BR112012030668A2 (pt) 2020-08-25
KR101847170B1 (ko) 2018-05-28
AU2011260745B2 (en) 2014-08-07
CA2799066C (en) 2019-07-23
MX2012013923A (es) 2013-01-24
US9145554B2 (en) 2015-09-29
US20130224313A1 (en) 2013-08-29
AR081259A1 (es) 2012-07-18
CN102917725A (zh) 2013-02-06
US20140206621A1 (en) 2014-07-24
ZA201208905B (en) 2013-07-31
RU2012157289A (ru) 2014-07-20
WO2011150897A2 (es) 2011-12-08
JP5827322B2 (ja) 2015-12-02
EP2578227A2 (en) 2013-04-10
CN102917725B (zh) 2014-09-17
RU2577993C2 (ru) 2016-03-20
DK2578227T3 (en) 2017-03-27
US8729226B2 (en) 2014-05-20
BR112012030668B1 (pt) 2022-03-29
UA112522C2 (uk) 2016-09-26
JP2013530162A (ja) 2013-07-25
AU2011260745A1 (en) 2012-12-06
CU23897B1 (es) 2013-05-31
KR20130089167A (ko) 2013-08-09
EP2578227B1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
EP4523696A3 (en) Enhanced adoptive cell therapy
GT201300215A (es) Inhibidores de glucosilceramida sintasa
MX2015012034A (es) El péptido mots3 derivado de mitocondrias regula el metabolismo y supervivencia celular.
EA201492055A1 (ru) ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
MX2016007063A (es) Peptidos terapeuticos.
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX369106B (es) Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
PH12014501844A1 (en) Peptidomimetic macrocycles
IN2014DN09098A (es)
NZ606195A (en) Methods and compositions for liver cancer therapy
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
IN2015DN00263A (es)
MX365403B (es) Peptidos y metodos para usarlos.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma

Legal Events

Date Code Title Description
FG Grant of patent